New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:36 EDTIDRAIdera announces expansion of pipeline into two orphan autoimmune diseases
Idera Pharmaceuticals announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The company plans to submit a protocol to the U.S. Food and Drug Administration in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
08:08 EDTIDRAIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 18, 2015
08:37 EDTIDRAIdera Pharmaceuticals appoints Joanna Horobin as Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use